SL-BioDP: Multi-Cancer Interactive Tool for Prediction of Synthetic Lethality and Response to Cancer Treatment
暂无分享,去创建一个
[1] Xiang Deng,et al. DiscoverSL: an R package for multi‐omic data driven prediction of synthetic lethality in cancers , 2018, Bioinform..
[2] Li Ding,et al. Comprehensive Characterization of Cancer Driver Genes and Mutations (vol 173, 371.e1, 2018) , 2018 .
[3] E. Ruppin,et al. Harnessing synthetic lethality to predict the response to cancer treatment , 2018, Nature Communications.
[4] Reena Philip,et al. FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non‐Small Cell Lung Cancers Harboring BRAF V600E Mutations , 2018, The oncologist.
[5] Alex H. Wagner,et al. DGIdb 3.0: a redesign and expansion of the drug–gene interaction database , 2017, bioRxiv.
[6] David S. Wishart,et al. DrugBank 5.0: a major update to the DrugBank database for 2018 , 2017, Nucleic Acids Res..
[7] Mark D. M. Leiserson,et al. Precision Oncology: The Road Ahead. , 2017, Trends in molecular medicine.
[8] R. Bernards,et al. A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma. , 2017, European urology.
[9] G. Mills,et al. Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers , 2017, Science Translational Medicine.
[10] Tae Min Kim,et al. Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. , 2016, The Lancet. Oncology.
[11] Hui Liu,et al. SynLethDB: synthetic lethality database toward discovery of selective and sensitive anticancer drug targets , 2015, Nucleic Acids Res..
[12] Andrea Bild,et al. Alternative preprocessing of RNA-Sequencing data in The Cancer Genome Atlas leads to improved analysis results , 2015, Bioinform..
[13] Gaurav Pandey,et al. Prediction of Genetic Interactions Using Machine Learning and Network Properties , 2015, Front. Bioeng. Biotechnol..
[14] L. Wong,et al. Inferring synthetic lethal interactions from mutual exclusivity of genetic events in cancer , 2015, Biology Direct.
[15] W. Sellers,et al. Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure , 2015, EMBO reports.
[16] Ellen T. Gelfand,et al. Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies , 2014, Scientific Data.
[17] Eytan Ruppin,et al. Predicting Cancer-Specific Vulnerability via Data-Driven Detection of Synthetic Lethality , 2014, Cell.
[18] P. Goodfellow,et al. Evaluation of incidence and prognostic significance of newly identified hotspot mutations in DNA polymerase epsilon (POLE) in endometrial cancer: Contextualizing findings from The Cancer Genome Atlas Research Network , 2014 .
[19] J. Hoheisel,et al. High throughput synthetic lethality screen reveals a tumorigenic role of adenylate cyclase in fumarate hydratase-deficient cancer cells , 2014, BMC Genomics.
[20] Joshua M. Stuart,et al. The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.
[21] Sridhar Ramaswamy,et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells , 2012, Nucleic Acids Res..
[22] Julian Downward,et al. Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies , 2012, Cell Research.
[23] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[24] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[25] Kevin R Brown,et al. Essential gene profiles in breast, pancreatic, and ovarian cancer cells. , 2012, Cancer discovery.
[26] Helga Thorvaldsdóttir,et al. Molecular signatures database (MSigDB) 3.0 , 2011, Bioinform..
[27] A. Ashworth,et al. Genetic Interactions in Cancer Progression and Treatment , 2011, Cell.
[28] Alan Ashworth,et al. Searching for synthetic lethality in cancer. , 2011, Current opinion in genetics & development.
[29] M. Dyer,et al. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. , 2010, Blood.
[30] Michael J. Emanuele,et al. A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene , 2009, Cell.
[31] A. Ashworth,et al. A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity. , 2008, DNA repair.
[32] W. Kaelin,et al. Kinase requirements in human cells: III. Altered kinase requirements in VHL−/− cancer cells detected in a pilot synthetic lethal screen , 2008, Proceedings of the National Academy of Sciences.
[33] Elizabeth Iorns,et al. A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor , 2008, The EMBO journal.
[34] Thomas Helleday,et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.
[35] Alan Ashworth,et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.
[36] I. Weinstein. Addiction to Oncogenes--the Achilles Heal of Cancer , 2002, Science.
[37] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.